Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micronized human amnion powder with or without methylprednisolone for medial and lateral elbow tendinopathy
IRCT20260610069744N1Phase 2Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of methylprednisolone in medial epicondylitis and Lateral Epicondylitis (LET) (3 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Pain severity, Daily functional activities and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
medial epicondylitisLateral Epicondylitis (LET)
Beyond the preview
Go deeper on IRCT20260610069744N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260610069744N1.